Armata Pharmaceuticals (ARMP) Amount of Cash per Share

Armata Pharmaceuticals (ARMP) develops treatments against resistant bacteria in US laboratories. The GURU.Markets platform tracks the cash per share trend, where 0.49 indicates the value of this parameter. High demand is driven by a unique platform of targeted phages that eliminate infections. Current viability relies on external capital and scientific potential until clinical trials are completed.
Comprehensive metric breakdowns and analytics for armatapharma.com (ARMP)

For Armata Pharmaceuticals (ARMP), which is developing innovative phage therapies against superbugs, this metric reflects the actual amount of liquidity per share net of all liabilities. By analyzing the quarterly trend of cash per share, an investor assesses the biotech brand's financial resilience against cash flow gaps, where growth in this metric confirms the availability of resources to complete costly clinical trials.